Nyrada (ASX: NYR) — Company Overview, News & Financial Data
Nyrada is a preclinical-stage drug development company specializing in the discovery and development of novel small molecule therapeutics for cardiovascular, neurodegenerative, and chronic inflammatory conditions.
Nyrada
Nyrada is a preclinical-stage drug development company specializing in the discovery and development of novel small molecule therapeutics for cardiovascular, neurodegenerative, and chronic inflammatory conditions. The company focuses on developing TRPC ion channel inhibitors and target-specific small molecules based around a benzopyran molecular scaffold to treat areas of significant unmet clinical need. Its primary research and development pipeline targets myocardial ischemia and arrhythmia control, stroke, traumatic brain injury, and autoimmune diseases. Through early-stage drug development and preclinical studies, Nyrada aims to advance targeted therapies where few effective treatment options currently exist.
Snapshot
Operations
Products and/or services of Nyrada
- Cardioprotection Program: Preclinical development of small molecule therapeutics targeting myocardial ischemia and arrhythmia control, aiming to minimize cardiac tissue damage and manage heart rhythm disruptions during acute cardiac ischemic events in cardiovascular patients.
- Stroke Neuroprotection: Preclinical drug development program targeting acute ischemic stroke to limit secondary neuronal cell loss, minimize neuroinflammation, and reduce long-term neurological disability in adult patients following ischemic brain injuries.
- Traumatic Brain Injury Therapeutics: Preclinical neuroprotectant drug development focused on treating acute traumatic brain injury to mitigate secondary brain damage, decrease cerebral tissue swelling, and improve long-term functional recovery following head trauma.
- PCSK9 Inhibitor Development: Cardiovascular drug candidate designed as a novel small molecule inhibitor of PCSK9 to lower elevated blood LDL-cholesterol levels in hypercholesterolemia patients who are intolerant of or non-responsive to statins.
- TRPC Ion Channel Inhibitors: Discovery and preclinical development of novel small molecule TRPC ion channel inhibitors engineered to regulate intracellular calcium entry, mitigating tissue necrosis and cellular degeneration across neurodegenerative and cardiovascular diseases.
- Autoimmune and Inflammatory Therapeutics: Preclinical drug discovery targeting chronic inflammatory conditions and autoimmune diseases, focusing on novel small molecules targeting TRPC ion channels and inflammatory pathways to manage peripheral nerve pain and psoriasis.
Nyrada executive team
- Mr. James BonnarCEO, MD & Director
- Mr. Cameron Peter Jones C.A.Chief Financial Officer
- Mr. Benjamin Evison Ph.D.Chief Scientific Officer
- Mr. Dimitri BurshteinInvestor Relations Manager
- Mr. Mark Waring B.Sc., P.M.P.Senior Vice President of US Operations
- Mr. David James Franks BEc, C.A., F Fin, J.P.Company Secretary